ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 10, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 10, 2011
News
Japan Halts Use of Pfizer and sanofi Vaccines
By Stephanie Sutton
Japan has suspended the use of two pediatric vaccines made by Pfizer and sanofi following the deaths of four children in three days.
Regulatory Roundup: FDA Posts PDUFA Meeting Minutes
FDA Posts PDUFA Meeting Minutes
Hamburg Describes Efforts to Develop Medical Countermeasures
By Erik Greb
At a conference on preserving national security at the University of Pittsburgh Medical Center last week, FDA Commissioner Margaret Hamburg stressed the importance of medical countermeasures for responding to natural and deliberate threats to public health.
AstraZeneca Discontinues Pulmicort Production
By Patricia Van Arnum
AstraZeneca announced this week that it will discontinue the production of Pulmicort (budesonide) 100 and 200 µg/dose HFA (hydrofluoroalkane) pressurized metered-dose inhaler (pMDI) due to manufacturing issues related to technical aspects of the device, which prevents the ongoing manufacture of the product.
Week of Mar. 7, 2011: Company and People Notes: WuXi and BMS Form Collaboration; F. Michael Ball Leaves Allergan for Hospira; and More.
WuXi and BMS Form Collaboration; F. Michael Ball Leaves Allergan for Hospira; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here